» Articles » PMID: 29596011

Slow Infusion of Recombinant Adeno-Associated Viruses into the Mouse Cerebrospinal Fluid Space

Overview
Publisher Mary Ann Liebert
Specialties Genetics
Pharmacology
Date 2018 Mar 30
PMID 29596011
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Recombinant adeno-associated viruses (rAAVs) are the leading in vivo gene delivery platform, and have been extensively studied in gene therapy targeting various tissues, including the central nervous system (CNS). A single-bolus rAAV injection to the cerebrospinal fluid (CSF) space has been widely used to target the CNS, but it suffers from several drawbacks, such as leakage to peripheral tissues. Here, a protocol is described using an osmotic pump to infuse rAAV slowly into the mouse CSF space. Compared to the single-bolus injection technique, pump infusion can lead to higher CNS transduction and lower transduction in the peripheral tissues.

Citing Articles

Intracranial Gene Delivery Mediated by Albumin-Based Nanobubbles and Low-Frequency Ultrasound.

Koga T, Kida H, Yamasaki Y, Feril Jr L, Endo H, Itaka K Nanomaterials (Basel). 2024; 14(3).

PMID: 38334557 PMC: 10856598. DOI: 10.3390/nano14030285.


Angiotensin-(1-7) reduces α-synuclein aggregation by enhancing autophagic activity in Parkinson's disease.

Gao Q, Chen R, Wu L, Huang Q, Wang X, Tian Y Neural Regen Res. 2021; 17(5):1138-1145.

PMID: 34558543 PMC: 8552854. DOI: 10.4103/1673-5374.324854.


Lentiviral Vectors Delivered with Biomaterials as Therapeutics for Spinal Cord Injury.

Shortiss C, Howard L, McMahon S Cells. 2021; 10(8).

PMID: 34440872 PMC: 8394044. DOI: 10.3390/cells10082102.


Megalencephalic Leukoencephalopathy: Insights Into Pathophysiology and Perspectives for Therapy.

Bosch A, Estevez R Front Cell Neurosci. 2021; 14:627887.

PMID: 33551753 PMC: 7862579. DOI: 10.3389/fncel.2020.627887.


Intrathecal Adeno-Associated Viral Vector-Mediated Gene Delivery for Adrenomyeloneuropathy.

Gong Y, Berenson A, Laheji F, Gao G, Wang D, Ng C Hum Gene Ther. 2018; 30(5):544-555.

PMID: 30358470 PMC: 6909708. DOI: 10.1089/hum.2018.079.

References
1.
Gurda B, de Guilhem de Lataillade A, Bell P, Zhu Y, Yu H, Wang P . Evaluation of AAV-mediated Gene Therapy for Central Nervous System Disease in Canine Mucopolysaccharidosis VII. Mol Ther. 2015; 24(2):206-216. PMC: 4817811. DOI: 10.1038/mt.2015.189. View

2.
Haurigot V, Marco S, Ribera A, Garcia M, Ruzo A, Villacampa P . Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy. J Clin Invest. 2013; 123(8):3254-3271. PMC: 3726158. DOI: 10.1172/JCI66778. View

3.
Meyer K, Ferraiuolo L, Schmelzer L, Braun L, McGovern V, Likhite S . Improving single injection CSF delivery of AAV9-mediated gene therapy for SMA: a dose-response study in mice and nonhuman primates. Mol Ther. 2014; 23(3):477-87. PMC: 4351452. DOI: 10.1038/mt.2014.210. View

4.
Hordeaux J, Dubreil L, Robveille C, Deniaud J, Pascal Q, Dequeant B . Long-term neurologic and cardiac correction by intrathecal gene therapy in Pompe disease. Acta Neuropathol Commun. 2017; 5(1):66. PMC: 5585940. DOI: 10.1186/s40478-017-0464-2. View

5.
Wang H, Yang B, Qiu L, Yang C, Kramer J, Su Q . Widespread spinal cord transduction by intrathecal injection of rAAV delivers efficacious RNAi therapy for amyotrophic lateral sclerosis. Hum Mol Genet. 2013; 23(3):668-81. PMC: 3888258. DOI: 10.1093/hmg/ddt454. View